European Healthcare M&A Outlook 2026: Resilience and Consolidation
Healthcare dealmakers have started the year with cautious optimism, and the European Healthcare M&A market is positioned to be one of the main M&A drivers for 2026. In 2025, macroeconomic uncertainty reduced transaction volumes across Europe, yet Spain outperformed other European markets with a more moderate drop. Here we’ll look at the details behind these market trends as analyzed in IMAP Spain’s recently published European Healthcare Mergers and Acquisitions Report.
European Healthcare M&A: Market context for 2025–2026
In Europe, Healthcare M&A transaction volumes contracted, even as investor interest in strategic acquisitions remained strong. Europe logged over 1.100 Healthcare deals in 2025-despite this contraction. The strongest quarter was Q1 with 356 transactions, while the other three quarters remained more or less stable, averaging 248 deals each. Macroeconomic uncertainty hit transaction numbers, leading to 279 fewer transactions in Europe compared to the previous year.
Yet the sector’s appeal endured. Buyers sought to enhance tech capabilities and footholds in adjacent markets, often through MedTech M&A and specialized medical devices platforms. Mid-sized platforms pursued build-up strategies in Imaging, Diagnostics, Medical Devices, Pharma Services, and premium Derma Segments, reinforcing the role of targeted Healthcare mergers and acquisitions in value creation.
Strategic vs financial buyers in European Healthcare M&A
European Healthcare investors can be broadly classified into two groups: strategic and financial buyers. In Q4 2025, strategic investors across Europe were active in cross-border Healthcare acquisitions, with a focus on capability expansion and therapeutic specialization.
For example, in the MedTech M&A space, EssilorLuxottica, a French ophthalmological company, acquired Optegra Eye Health Care, a UK-based integrated ophthalmology platform, strengthening its position in specialized eye-care services. In another Q4 strategic transaction, Netherlands-headquartered Affidea, a leading pan-European Healthcare group specializing in advanced diagnostic imaging, outpatient services, cancer treatment, and laboratory medicine, acquired Alfamed Patomorfologia, a Polish laboratory focused on histopathology, cytology and molecular tests for medical facilities. These cross-border Healthcare acquisitions underscore a broader push for technological augmentation and geographic diversification across European Healthcare.
Financial buyers, meanwhile, pursued operational transformation and platform scaling as part of their European Healthcare M&A strategies. In the final quarter of 2025, this was exemplified by French Healthcare investment fund Archimed’s acquisition of ZimVie, an American producer of orthopedic innovations, as well as UK CVC Capital Partners’ purchase of Grupo GSH in Brazil, its first large investment in South America and one which expands its capabilities in the Brazilian Healthcare sector.
Spanish Healthcare M&A Spotlight
Spain bucked Europe’s downturn with a moderate decline and solidified its position as one of the continent’s most dynamic Healthcare M&A markets. Spanish firms featured in 141 of Europe’s 1.100+ 2025 deals. Cross-border activity comprised 51% overall - outbound to Portugal, Germany, the U.S. and Italy; inbound led by the UK, US, Sweden, and Germany - highlighting Spain’s role as a gateway for cross-border Healthcare acquisitions.
Q4 2025 marked the year’s peak with 44 transactions, nearly 20% of European volume that period. Investors split at 52% strategic - led by nationals - and 48% financial, with deals balanced at 50% cross-border and 50% domestic.
Hospitals and Clinics, at 36.4% of deals, led the subsectors, driven by private equity platforms in ophthalmology and aesthetic medicine - illustrating ongoing hospital consolidation trends in Spain. Elderly Care M&A, particularly nursing homes, followed at 18.2%. MedTech and Derma/Cosmetics tied at 13.7% each, while Pharma reached 11.4%, reflecting diversified interest across Medical Devices, Specialized Care, and Pharmaceuticals.
Three Strategic Rationales Driving Healthcare M&A in Spain
Investors’ strategic rationales were diverse, but can be classified into three main areas:
-
International companies entering or reinforcing their position in the Spanish market: Examples include Affidea of the Netherlands’ purchase of Clinica Orcube in October 2025, Medinfar of Portugal’s acquisition of Peroxfarma in November, and Cosnova of Germany’s purchase of Niche Beauty Lab in December
-
Spanish companies consolidating their position in the national or international market: Illustrative deals include Miranza’s purchase of Institut Oftalmològic de Catalunya in October, Impress’s acquisition of Swedish Smajla in October, and Pyd’s purchase of Twelve Beauty in November
-
Private equity companies accessing and consolidating in the Spanish market: Notable examples are ProA Capital’s purchase of Klockner Medical Group in October, Stellum Capital’s acquisition of Laboratorios Bilper Group in November, and German Carbyne’s purchase of Suannutra in December
Spanish Deals to Watch in 2026 (The Pipeline)
Looking ahead, the report consolidates information on a visible pipeline of transactions that should keep Spanish Healthcare firmly on the M&A agenda in 2026.
-
On the biopharma manufacturing side, Keensight Capital is preparing the sale of 3P Biovian, a Spanish biotech CDMO specializing in complex biological medicines for third parties, illustrating ongoing interest in high-value pharmaceutical contract manufacturing
-
Buenavista is working towards an exit from Vitro Master Diagnóstica, a Spanish diagnostics group expected to achieve a valuation of more than EUR 400 million in the first half of the year
-
In parallel, Karo Healthcare is actively scouting consumer-health brands in Digestive and Skincare across core European markets, adding a consumer-health angle to Europe Healthcare M&A activity
-
Bimedica plans further acquisitions in its existing territories to deepen customer relationships and consolidate distribution channels, reinforcing Medical Devices and Supplies platforms
-
Corus, the Spanish company focused on dental prostheses, is pursuing an ambitious inorganic growth strategy in Spain and abroad ahead of a planned sale in 2026
Together, these mid-market and upper-mid-market processes are set to shape the next phase of European Healthcare M&A, combining Specialized Services, Diagnostics, MedTech M&A, and Pharma Manufacturing.
IMAP’s Healthcare M&A Footprint
IMAP highlights this dynamism within European Healthcare mergers and acquisitions. Since 2015, the partnership has executed 222 Healthcare transactions globally, averaging around 22 annually. 25% of these were cross-border deals and more than 65% involved European target companies, underlining its experience in cross-border Healthcare acquisitions. Subsectors split as 54% Hospitals and Clinics, 23% Medical Devices, 11% Pharma, 8% Auxiliary Services, 2% Beauty – Dermatology and Cosmetics, and 2% Nursing homes, reflecting broad exposure across hospital consolidation trends, Medical Devices and Elderly care M&A.
As 2026 unfolds, the European Healthcare M&A landscape is poised to balance caution with opportunity, as resilient investors continue to pursue innovation, specialization, and cross-border growth across an increasingly integrated healthcare ecosystem.
Click HERE to download the full Healthcare Report by IMAP Spain.
